Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BMS-690514
BMS-690514/ FOLFIRI · 7 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| BMS-690514 | EXPERIMENTAL | - |
| BMS-690514 + Letrozole | ACTIVE_COMPARATOR | - |
| Lapatinib + Letrozole | ACTIVE_COMPARATOR | - |
| A1 | EXPERIMENTAL | - |
| B2 | ACTIVE_COMPARATOR | - |
| 1 | EXPERIMENTAL | - |
| A | ACTIVE_COMPARATOR | - |
| B | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-690514 | DRUG | Tablets, Oral, 200 mg, once daily, until disease progression or toxicity |
| Lapatinib | DRUG | Tablets, Oral, 1500 mg, once daily, \~ 12 months depending on response |
| Letrozole | DRUG | Tablets, Oral, 2.5 mg, once daily, \~ 12 months depending on response |
| Erlotinib | DRUG | Capsules, Oral, 150 mg, once daily, Until disease progression or toxicity |
| BMS-690514 / FOLFIRI | DRUG | Tablets / IV, Oral / IV, up to 200 mg / irinotecan 180mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos |
| BMS-690514 / FOLFOX | DRUG | Tablets / IV, Oral / IV, up to 200 mg / oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos |
Inclusion Criteria: * Recurrent, metastatic or progressive NSCLC without any indication of radiotherapy. Subjects must have: * Pathologically confirmed NSCLC * Previously received treatment with single agent Gefitinib or Erlotinib and completed treatment at least 2 weeks prior to study entry * Any ...
Top 20 of 87 competitors
BMS-690514/FOLFIRI refers to the investigational small molecule BMS-690514 evaluated in combination with FOLFIRI chemotherapy. BMS-690514 was developed by Bristol-Myers Squibb Company (BMY) and studied in solid tumors, including non-small cell lung cancer and breast cancer. It remains an investigational agent and is not approved for any indication.
BMS-690514 targets EGFR, ERBB2, ERBB4, KDR, FLT1, and FLT4. It is a small molecule inhibitor of these receptor tyrosine kinases, which are involved in tumor cell proliferation and angiogenesis. This multi-target profile distinguishes it from agents that inhibit only EGFR.
Bristol-Myers Squibb Company (ticker: BMY) developed BMS-690514. The FOLFIRI component is a standard chemotherapy regimen, not a proprietary product of Bristol-Myers Squibb. Bristol-Myers Squibb sponsored the clinical trials of BMS-690514, including the combination studies.
BMS-690514 is in Phase 2 development. Four clinical trials have been completed, including Phase 1 and Phase 2 studies, with no active trials ongoing. The drug is investigational and has not been approved by the FDA for any indication.
BMS-690514 has been studied in four completed trials: NCT01167244 in EGFR mutation positive non-small cell lung cancer in Japan, NCT01068704 with letrozole in metastatic breast cancer, NCT00743938 comparing BMS-690514 with erlotinib in previously treated NSCLC, and NCT00516451 in Japanese patients with solid tumors.